Equities research analysts expect Icon Plc (NASDAQ:ICLR) to report earnings per share (EPS) of $1.32 for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Icon Plc’s earnings, with estimates ranging from $1.27 to $1.37. Icon Plc reported earnings per share of $1.19 during the same quarter last year, which indicates a positive year over year growth rate of 10.9%. The company is expected to issue its next earnings report on Thursday, October 19th.

On average, analysts expect that Icon Plc will report full year earnings of $5.31 per share for the current fiscal year, with EPS estimates ranging from $5.27 to $5.37. For the next financial year, analysts forecast that the firm will report earnings of $5.91 per share, with EPS estimates ranging from $5.77 to $6.06. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Icon Plc.

Icon Plc (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.01. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The business had revenue of $431.00 million during the quarter, compared to the consensus estimate of $430.68 million. During the same quarter in the prior year, the firm earned $1.14 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis.

A number of brokerages recently issued reports on ICLR. Jefferies Group LLC restated a “buy” rating and set a $122.00 price objective on shares of Icon Plc in a report on Tuesday. Bank of America Corporation began coverage on shares of Icon Plc in a report on Monday. They set a “buy” rating and a $128.00 price objective for the company. Zacks Investment Research upgraded shares of Icon Plc from a “hold” rating to a “buy” rating and set a $131.00 price objective for the company in a report on Saturday, September 9th. ValuEngine upgraded shares of Icon Plc from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Finally, BidaskClub upgraded shares of Icon Plc from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $113.67.

WARNING: “$1.32 EPS Expected for Icon Plc (ICLR) This Quarter” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/14/1-32-eps-expected-for-icon-plc-iclr-this-quarter.html.

Icon Plc (NASDAQ:ICLR) traded down 0.55% during midday trading on Thursday, reaching $111.91. 150,238 shares of the company’s stock were exchanged. Icon Plc has a 1-year low of $73.76 and a 1-year high of $117.53. The stock has a market cap of $6.05 billion, a P/E ratio of 22.70 and a beta of 0.61. The firm’s 50-day moving average is $107.29 and its 200 day moving average is $92.96.

Several institutional investors have recently added to or reduced their stakes in ICLR. Canada Pension Plan Investment Board boosted its holdings in shares of Icon Plc by 155.6% in the first quarter. Canada Pension Plan Investment Board now owns 13,140 shares of the medical research company’s stock valued at $1,048,000 after buying an additional 8,000 shares during the period. US Bancorp DE boosted its holdings in shares of Icon Plc by 15.0% in the first quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock valued at $154,000 after buying an additional 251 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Icon Plc by 4.0% in the first quarter. Bank of New York Mellon Corp now owns 310,788 shares of the medical research company’s stock valued at $24,777,000 after buying an additional 11,892 shares during the period. World Asset Management Inc boosted its holdings in shares of Icon Plc by 1.8% in the first quarter. World Asset Management Inc now owns 3,455 shares of the medical research company’s stock valued at $275,000 after buying an additional 60 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its holdings in shares of Icon Plc by 2.1% in the first quarter. UBS Asset Management Americas Inc. now owns 239,769 shares of the medical research company’s stock valued at $19,114,000 after buying an additional 4,951 shares during the period. Institutional investors own 90.62% of the company’s stock.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Get a free copy of the Zacks research report on Icon Plc (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.